Articles
Clinical Monographs
In-depth, citation-backed writing on clinical monographs. · 10 articles in Clinical Monographs
Does CRB-913's Peripherally Restricted CB1 Inverse Agonism Offer a Clinically Meaningful Non-Incretin Obesity Mechanism in 2026?
Yes, with important caveats. CRB-913's 2026 CANYON-1 Phase 1b readout showed 5% placebo-adjusted weight loss at 60 mg over 12 weeks with a clean neuropsychiatric safety profile, establishing peripheral CB1 inverse agonism as a mechanistically distinct, non-incretin obesity pathway. The mechanism operates through leptin-resistance reversal and direct adipose and hepatic lipid suppression, positioning it as a complement to GLP-1/GIP therapies.
Can TS-104, a First-in-Class Peptide-Drug Conjugate, Achieve a Tolerable Dose-Escalation Profile in Solid Tumors Without Dose-Limiting Toxicity in 2026?
TS-104 is a first-in-class, fully synthetic peptide-drug conjugate that couples a polyspecific integrin-binding peptide (PIP) to the cytotoxin MMAE. Whether it achieves a tolerable dose-escalation profile without dose-limiting toxicity in humans remains open: FDA IND clearance was granted in September 2026, and the first-in-human Phase 1 trial (NCT07814248) is now enrolling patients with advanced solid tumors.
What Does 2026 Research Reveal About Semaglutide's Neuroprotective Potential, and Why Did the EVOKE Trials Fail to Confirm It?
A 2026 review in Frontiers in Aging Neuroscience (Alhowail) concludes that semaglutide's neuroprotective mechanisms — GLP-1 receptor activation in the brain, reduced neuroinflammation, improved cerebral glucose metabolism, and attenuation of amyloid-β and tau pathology — are well-supported preclinically. The EVOKE and EVOKE+ Phase 3 trials found no cognitive benefit in established Alzheimer's disease, shifting the hypothesis toward early prevention.
How Does Mazdutide's Dose-Response Relationship in the 2026 U.S. Phase 2 Trial Inform Phase 3 Dose Selection for Obesity?
The 2026 United States phase 2 mazdutide trial produced placebo-corrected weight reductions of 6%, 14%, and 17% at week 32 across 3–6 mg, 10 mg, and 16 mg arms. The dose-response curve was monotonic but non-linear. The 10 mg arm captured most of the efficacy gain with tolerability burden comparable to approved agents, making it the leading phase 3 candidate.
What Did the First U.S. Phase 2 Mazdutide Trial Show for Weight Loss, HbA1c, and Tolerability in 2026?
The first United States phase 2 trial of mazdutide reported dose-dependent weight reductions of up to 18% at 32 weeks in adults with obesity or overweight. Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist. All active doses produced significant HbA1c decreases versus placebo. Gastrointestinal adverse events were the dominant tolerability signal with discontinuation rates reaching 20% at 16 mg.
Does Retatrutide Improve Liver Disease Outcomes Beyond Weight Loss in 2026 Preclinical and Translational Evidence?
Preclinical and translational data through 2026 indicate that retatrutide reduces hepatic steatosis and inflammation through mechanisms extending beyond caloric-deficit-driven weight loss. Glucagon receptor co-agonism drives direct hepatic fatty acid oxidation and suppresses de novo lipogenesis, while GLP-1 receptor activity attenuates hepatic inflammation via NF-κB inhibition. Whether these weight-independent pathways translate to durable fibrosis regression in humans remains an open question.
Does the 2026 BPC-157 Hamstring Strain RCT (NCT07437547) Use MRI Injury Volume and Return-to-Sport as Co-Primary Endpoints?
Yes. NCT07437547, a Phase 2 randomised, double-blind, placebo-controlled trial currently recruiting in 2026, designates two co-primary endpoints: time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14. The trial enrols 120 adults with MRI-confirmed acute grade II hamstring strain and administers subcutaneous BPC-157 or placebo once daily for 14 days alongside a standardised rehabilitation programme.
Does Pemvidutide Improve Alcohol Use Disorder Outcomes in Patients With Obesity — What Did the July 2026 RECLAIM Study Report?
Yes. The July 2026 RECLAIM Phase 2 trial reported that pemvidutide, a balanced GLP-1/glucagon dual receptor agonist developed by Altimmune, significantly reduced heavy drinking days and total alcohol consumption in adults with comorbid obesity and alcohol use disorder. Participants also achieved clinically meaningful weight loss, indicating simultaneous benefit across both conditions.
What Human Safety and Efficacy Data Support MOTS-c for Metabolic or Longevity Indications After the 2026 FDA Review?
As of 2026, MOTS-c lacks approved human clinical trial data for any metabolic or longevity indication. The available human evidence is limited to observational studies linking endogenous circulating MOTS-c levels to insulin sensitivity and aging phenotypes, one small exercise-intervention study, and preclinical mechanistic work. The FDA's 2026 review placed it under compounding scrutiny without an approved NDA.
What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile?
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 development. It demonstrated up to 24.2% mean body-weight reduction at 48 weeks in its pivotal Phase 2 trial. Emerging 2026 analyses confirm robust efficacy but flag dose-dependent gastrointestinal adverse events and a persistent resting heart-rate elevation as the primary safety signals requiring ongoing risk-benefit evaluation.